{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:47:14Z","timestamp":1790858834758,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T00:00:00Z","timestamp":1637452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T00:00:00Z","timestamp":1637452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The foundation of Linn\u00e9a and Joseph Carlsson"},{"name":"The foundation for Bo-G\u00f6ran Bremert\u00b4s memory"},{"name":"the Swedish fundraising foundation for Muscular Dystrophy Research"},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder with increasing life expectancy from late teens to over 30\u00a0years of age. The aim of this nationwide study was to explore the prevalence, life expectancy and leading causes of death in patients with DMD in Sweden. Patients with DMD were identified through the National Quality Registry for Neuromuscular Diseases in Sweden, the Swedish Registry of Respiratory Failure, pathology laboratories, neurology and respiratory clinics, and the national network for neuromuscular diseases. Age and cause of death were retrieved from the Cause of Death Registry and cross-checked with medical records. 373 DMD patients born 1970\u20132019 were identified, of whom 129 patients deceased during the study period. Point prevalence of adult patients with DMD on December 31st 2019 was 3.2 per 100,000 adult males. Birth prevalence was 19.2 per 100,000 male births. Median survival was 29.9\u00a0years, the leading cause of death being cardiopulmonary in 79.9% of patients. Non-cardiopulmonary causes of death (20.1% of patients) mainly pertained to injury-related pulmonary embolism (1.3 per 1000 person-years), gastrointestinal complications (1.0 per 1000 person-years), stroke (0.6 per 1000 person-years) and unnatural deaths (1.6 per 1000 person-years). Death from non-cardiopulmonary causes occurred at younger ages (mean 21.0\u00a0years, SD 8.2; <jats:italic>p<\/jats:italic>\u2009=\u20090.004). Age at loss of independent ambulation did not have significant impact on overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.26). We found that non-cardiopulmonary causes contribute to higher mortality among younger patients with DMD. We present novel epidemiological data on the increasing population of adult patients with DMD.<\/jats:p>","DOI":"10.1007\/s10654-021-00819-4","type":"journal-article","created":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T04:27:23Z","timestamp":1637468843000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-6991","authenticated-orcid":false,"given":"Lisa","family":"Wahlgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Kroksmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tulinius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Sofou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,21]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020. https:\/\/doi.org\/10.1186\/s13023-020-01430-8.","journal-title":"Orphanet J Rare Dis"},{"key":"819_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-8966(99)00055-3","author":"N Darin","year":"2000","unstructured":"Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord NMD. 2000. https:\/\/doi.org\/10.1016\/s0960-8966(99)00055-3.","journal-title":"Neuromuscul Disord NMD."},{"key":"819_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4.","journal-title":"Cell"},{"key":"819_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(03)00585-4","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003. https:\/\/doi.org\/10.1016\/s1474-4422(03)00585-4.","journal-title":"Lancet Neurol"},{"key":"819_CR5","volume-title":"Muscle disorders in childhood","author":"V Dubowitz","year":"1995","unstructured":"Dubowitz V. Muscle disorders in childhood. 2nd ed. London: Saunders; 1995.","edition":"2"},{"key":"819_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30024-3","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"key":"819_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-199509001-00003","author":"CM McDonald","year":"1995","unstructured":"McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995. https:\/\/doi.org\/10.1097\/00002060-199509001-00003.","journal-title":"Am J Phys Med Rehabil"},{"key":"819_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)07815-7","author":"AE Emery","year":"2002","unstructured":"Emery AE. The muscular dystrophies. Lancet. 2002. https:\/\/doi.org\/10.1016\/s0140-6736(02)07815-7.","journal-title":"Lancet"},{"key":"819_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2016.07.020","author":"HJ Van Ruiten","year":"2016","unstructured":"Van Ruiten HJ, Marini Bettolo C, Cheetham T, et al. Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. Eur J Paediatr Neurol EJPN. 2016. https:\/\/doi.org\/10.1016\/j.ejpn.2016.07.020.","journal-title":"Eur J Paediatr Neurol EJPN."},{"issue":"2","key":"819_CR10","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121\u20135.","journal-title":"Acta Myol"},{"key":"819_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2013.06.002","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013. https:\/\/doi.org\/10.1016\/j.rehab.2013.06.002.","journal-title":"Ann Phys Rehabil Med"},{"key":"819_CR12","doi-asserted-by":"publisher","unstructured":"Gozal D. Pulmonary manifestations of neuromuscular disease with special reference to Duchenne muscular dystrophy and spinal muscular atrophy. Pediatr Pulmonol. 2000; https:\/\/doi.org\/10.1002\/(sici)1099-0496(200002)29:2<141::aid-ppul9>3.0.co;2-y","DOI":"10.1002\/(sici)1099-0496(200002)29:2<141::aid-ppul9>3.0.co;2-y"},{"key":"819_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2009.00404.x","author":"RW Kaspar","year":"2009","unstructured":"Kaspar RW, Allen HD, Montanaro F. Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract. 2009. https:\/\/doi.org\/10.1111\/j.1745-7599.2009.00404.x.","journal-title":"J Am Acad Nurse Pract"},{"key":"819_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5273(90)90082-g","author":"G Nigro","year":"1990","unstructured":"Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990. https:\/\/doi.org\/10.1016\/0167-5273(90)90082-g.","journal-title":"Int J Cardiol"},{"key":"819_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23215","author":"DJ Birnkrant","year":"2016","unstructured":"Birnkrant DJ, Ararat E, Mhanna MJ. Cardiac phenotype determines survival in Duchenne muscular dystrophy. Pediatr Pulmonol. 2016. https:\/\/doi.org\/10.1002\/ppul.23215.","journal-title":"Pediatr Pulmonol"},{"key":"819_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32160-8","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018. https:\/\/doi.org\/10.1016\/s0140-6736(17)32160-8.","journal-title":"Lancet"},{"key":"819_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-8966(02)00140-2","author":"M Eagle","year":"2002","unstructured":"Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord NMD. 2002. https:\/\/doi.org\/10.1016\/s0960-8966(02)00140-2.","journal-title":"Neuromuscul Disord NMD"},{"key":"819_CR18","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.00831","author":"JR Bach","year":"2011","unstructured":"Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care. 2011. https:\/\/doi.org\/10.4187\/respcare.00831.","journal-title":"Respir Care"},{"key":"819_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.09.006","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord NMD. 2011. https:\/\/doi.org\/10.1016\/j.nmd.2010.09.006.","journal-title":"Neuromuscul Disord NMD."},{"key":"819_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2008.08.013","author":"H Ogata","year":"2009","unstructured":"Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009. https:\/\/doi.org\/10.1016\/j.jjcc.2008.08.013.","journal-title":"J Cardiol"},{"key":"819_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-282x2010000500002","author":"SL Parreira","year":"2010","unstructured":"Parreira SL, Resende MB, Zanoteli E, Carvalho MS, Marie SK, Reed UC. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy. Arq Neuropsiquiatr. 2010. https:\/\/doi.org\/10.1590\/s0004-282x2010000500002.","journal-title":"Arq Neuropsiquiatr"},{"key":"819_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810371004","author":"RT Moxley 3rd","year":"2010","unstructured":"Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010. https:\/\/doi.org\/10.1177\/0883073810371004.","journal-title":"J Child Neurol"},{"key":"819_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.01.010","author":"WD Biggar","year":"2006","unstructured":"Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord NMD. 2006. https:\/\/doi.org\/10.1016\/j.nmd.2006.01.010.","journal-title":"Neuromuscul Disord NMD."},{"key":"819_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001950","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology. 2015. https:\/\/doi.org\/10.1212\/wnl.0000000000001950.","journal-title":"Neurology"},{"key":"819_CR25","volume-title":"Diagnostic Criteria for Neuromuscular Disorders","author":"AEH Emery","year":"1994","unstructured":"Emery AEH. Diagnostic Criteria for Neuromuscular Disorders. 2nd ed. Barn: European Neuromuscular Centre; 1994.","edition":"2"},{"key":"819_CR26","doi-asserted-by":"crossref","unstructured":"Stromberg A, Darin N, Kroksmark A. K. et al. What was the age and cause of death in patients with Duchenne muscular dystrophy in Sweden during 2000\u20132010? 2012. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960896612004385. Accessed 27 May 2021.","DOI":"10.1016\/j.nmd.2012.06.256"},{"key":"819_CR27","doi-asserted-by":"publisher","DOI":"10.36185\/2532-1900-001","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, M\u00fcller CK, Pechmann A, et al. Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. Acta Myol. 2020. https:\/\/doi.org\/10.36185\/2532-1900-001.","journal-title":"Acta Myol"},{"key":"819_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.6.585","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998. https:\/\/doi.org\/10.1001\/archinte.158.6.585.","journal-title":"Arch Intern Med"},{"key":"819_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.06.023","author":"F Nozaki","year":"2019","unstructured":"Nozaki F, Kusunoki T, Kumada T, Shibata M, Fujii T. Risk factors for cerebral infarction in Duchenne muscular dystrophy: review with our 2 cases. J Stroke Cerebrovasc Dis. 2019. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.06.023.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"819_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.116.013678","author":"M Winterholler","year":"2016","unstructured":"Winterholler M, Holl\u00e4nder C, Kerling F, et al. Stroke in Duchenne muscular dystrophy: a retrospective longitudinal study in 54 patients. Stroke. 2016. https:\/\/doi.org\/10.1161\/strokeaha.116.013678.","journal-title":"Stroke"},{"key":"819_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.113.001170","author":"A Rosengren","year":"1987","unstructured":"Rosengren A, Giang KW, Lappas G, Jern C, Tor\u00e9n K, Bj\u00f6rck L. Twenty-four-year trends in the incidence of ischemic stroke in Sweden from to 2010. Stroke. 1987. https:\/\/doi.org\/10.1161\/strokeaha.113.001170.","journal-title":"Stroke"},{"key":"819_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci113","author":"AE Parker","year":"2005","unstructured":"Parker AE, Robb SA, Chambers J, et al. Analysis of an adult Duchenne muscular dystrophy population. QJM. 2005. https:\/\/doi.org\/10.1093\/qjmed\/hci113.","journal-title":"QJM"},{"key":"819_CR33","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0333I","author":"S Buddhe","year":"2018","unstructured":"Buddhe S, Cripe L, Friedland-Little J, et al. Cardiac management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018. https:\/\/doi.org\/10.1542\/peds.2018-0333I.","journal-title":"Pediatrics"},{"key":"819_CR34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0333H","author":"DW Sheehan","year":"2018","unstructured":"Sheehan DW, Birnkrant DJ, Benditt JO, et al. Respiratory management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018. https:\/\/doi.org\/10.1542\/peds.2018-0333H.","journal-title":"Pediatrics"},{"key":"819_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020. https:\/\/doi.org\/10.1007\/s10654-020-00613-8.","journal-title":"Eur J Epidemiol"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-021-00819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-021-00819-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-021-00819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T14:23:52Z","timestamp":1648477432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-021-00819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,21]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s10654-021-00819-4","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,21]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Swedish Ethics Committee (Dnr. 1130\u201311 and 2019\u201301790).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This research study was conducted retrospectively from data obtained from registries and the patients\u2019 medical records. The Swedish Ethics Committee decided that informed consent from the families <i>should not<\/i> be collected.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}